PainReform Ltd
PRFX
Get informed when a big investor buys or sells
+ FollowMarket Cap$74.09K
Close$
$6.42
625.6% upside
Current Fair Value
625.6% upsideUndervalued by 625.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $74,089.00 |
|---|---|
| Enterprise Value | $-8,401,911.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.47 |
| Beta | 1.04 |
| Outstanding Shares | 1,244,482 |
Return
| Return on Equity | -33.51% |
|---|---|
| Return on Assets | -27.86% |
| Return on Invested Capital | -31.59% |
Valuation & Multiples
| P/E Ratio | -0.08 |
|---|---|
| PEG | -0.4 |
| Price to Sales | - |
| Price to Book Ratio | 0.07 |
| Enterprise Value to Revenue | -271.03 |
| Enterprise Value to EBIT | 1.59 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 2, 2026
EPS Estimate
$-612.00
Average shareholder expectationRevenue Estimate
$7,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 31.38%▲ 28.95% |
|---|---|
| Total Invested | $280,557▲ 778.42% |
| Investors Holding | 7▲ 3.00% |
ESG Score
No data
About PainReform Ltd
2 employeesPainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company's lead product, is based on the local anesthetic ropivacaine, targeting the post-operative pai...